Johnson & Johnson TRAUMA — Percent Change (as a percent) increased by 231.7% to 13.6% in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 58.1%, from 8.6% to 13.6%. This is a positive signal — higher values indicate stronger performance for this metric.
A positive percentage indicates organic or inorganic growth in the trauma segment, whereas a negative percentage suggests a contraction in sales volume or pricing power within the trauma market.
This metric measures the period-over-period growth rate of revenue generated from the trauma product line. It isolates t...
Comparable to the organic or reported revenue growth rates of specific medical device product lines at diversified healthcare competitors.
jnj_segment_trauma_percent_change_as_a_percent| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 37.2% | 87.1% | 11.9% | 38.7% | 4.3% | -9.8% | -2% | 2% | 10.9% | 1.5% | 8.2% | 8.6% | 4.1% | 4.1% | 13.6% |
| QoQ Change | — | +134.1% | -86.3% | +225.2% | -88.9% | -327.9% | +79.6% | +200.0% | +445.0% | -86.2% | +446.7% | +4.9% | -52.3% | -0.0% | +231.7% |
| YoY Change | — | — | — | — | -88.4% | -111.3% | -116.8% | -53.5% | +211.2% | — | +310.0% | -21.1% | +173.3% | -50.0% | +58.1% |
We use cookies for analytics. See our Privacy and Cookie Policy.